Literature DB >> 8827053

Heparin reverses Rhodamine 123 extrusion by multidrug resistant cells.

R C Maia1, K Wagner, R H Cabral, V M Rumjanek.   

Abstract

The effect of heparin as a reversing agent of multidrug resistance (MDR) was tested on normal mononuclear cells from 24 healthy volunteers and leukaemic cells from 12 acute myeloid leukaemia, five chronic myeloid leukaemia, five acute lymphoid leukaemia and three chronic lymphoid leukaemia patients. Two cell lines were used as controls, the human erythroleukaemia K562 and its vincristine-resistant derivative K562-Lucena 1. Heparin was not cytotoxic by itself as determined using a MTT assay and cell counts. MDR modulation was assessed by Rhodamine 123 extrusion using flow-cytometry. Modulation of the resistant cell line was produced by the classical reversing agent verapamil and also by heparin, the same being observed in normal and leukaemic cells and being independent of the type of leukaemia. Our work suggests that heparin may be considered a potential MDR modulator.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827053     DOI: 10.1016/0304-3835(96)04309-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  OCT4 mutations in human erythroleukemic cells: implications for multiple drug resistance (MDR) phenotype.

Authors:  Bruno Rodrigues Oliveira; Marcio Azevedo Figueiredo; Gilma Santos Trindade; Luis Fernando Marins
Journal:  Mol Cell Biochem       Date:  2014-10-30       Impact factor: 3.396

Review 2.  Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans.

Authors:  Ilaria Marrocco; Fabio Altieri; Ilaria Peluso
Journal:  Oxid Med Cell Longev       Date:  2017-06-18       Impact factor: 6.543

3.  Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation.

Authors:  Qi Niu; Wei Wang; Yong Li; Douglas M Ruden; Fenghua Wang; Yue Li; Fangying Wang; Jingying Song; Kun Zheng
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.